<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422487</url>
  </required_header>
  <id_info>
    <org_study_id>M2044-20610</org_study_id>
    <nct_id>NCT00422487</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of MBX-2044 to Evaluate the Multiple-dose Pharmacokinetics, Safety and Tolerability When Administered Orally in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect important information regarding the glucose-lowering
      efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in
      diabetics. It will also provide important information about the appropriate doses to be used
      in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044 alone and
      in combination with other anti-diabetic agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed to test the short-term effectiveness and tolerability of
      MBX-2044 in patients with type 2 diabetes who are currently being controlled with up to one
      or two non-TZD hypoglycemic agent(s) including sulfonylureas, meglitinides, metformin,
      α-glucosidase inhibitors or Byetta®. Eligible patients will be enrolled into one of the
      following treatment cohorts receiving either placebo or MBX-2044 at 1.5, 4.5, 15, 30, or 60
      mg/day in a double-blinded study for a 14-day treatment period. Patients will be evaluated
      for adverse events and vital signs daily. All efficacy and laboratory safety measures will be
      assessed after 2 weeks. This study will provide important information regarding the
      glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and
      edema) in diabetics. It will also provide important information about the appropriate doses
      to be used in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044
      alone and in combination with other anti-diabetic agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the multiple-dose pharmacokinetics of MBX-2044 administered as monotherapy at the protocol-specified daily dose orally for 14 days</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the clinical safety and tolerability of MBX-2044 after 14 days administration, including the parameters of weight gain and edema</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of MBX-2044, after 14 days administration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the effect of MBX-2044 after 14 days administration, on efficacy parameters</measure>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MBX-2044 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2044 4.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2044 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2044 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2044 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2044 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 1.5 mg one capsule daily for 14 days</description>
    <arm_group_label>MBX-2044 1.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days</description>
    <arm_group_label>MBX-2044 4.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 15 mg one capsule daily for 14 days</description>
    <arm_group_label>MBX-2044 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 30 mg two 15 mg capsules daily for 14 days</description>
    <arm_group_label>MBX-2044 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 60 mg one capsule daily for 14 days</description>
    <arm_group_label>MBX-2044 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2044</intervention_name>
    <description>MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days</description>
    <arm_group_label>MBX-2044 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MBX-2044</intervention_name>
    <description>Placebo Intervention</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes previously controlled with up to one or two non-TZD hypoglycemic
             agents including sulfonylureas (e.g., glyburide, glipizide, glimeprimide),
             meglitinides (e.g., Prandin®, Starlix®), metformin (e.g., Glucophage®), α-glucosidase
             inhibitors (e.g.,acarbose, miglitol) or Byetta®

          -  All female patients must be either surgically sterile or post-menopausal.

          -  Male patients with female partners of childbearing potential must agree to use
             condoms, or their partner must use a medically acceptable form of contraception.

          -  BMI 24-44 kg/m2.

          -  Patients must have a FPG ≤ 200 mg/dL at screening.

          -  Patients must have Hemoglobin A1c ≥ 6.5%, ≤ 10.0% at screening.

          -  Electrocardiogram (ECG) and chest x-ray must be normal, or considered not clinically
             significant, for participation in this study.

          -  Patients must have a blood pressure ≤ 160/90 mm/hg including hypertensive patients
             controlled with medication.

        Exclusion Criteria:

          -  History of Type 1 diabetes or diabetes secondary to pancreatitis or pancreatectomy.

          -  History of TZD use (Actos or Avandia) within 6 months of Screening Visit.

          -  History of TZD discontinuation due to lack of efficacy.

          -  History of congestive heart failure within last 5 years.

          -  History of significant pulmonary disease, myocardial infarction, cerebrovascular
             accident, or nephrotic syndrome within last 1 year.

          -  Malignancy within the last 5 years (except resected basal cell carcinoma).

          -  Ongoing active infection.

          -  Change in treatment with lipid-lowering agent within 7 days of screening visit.

          -  Current or expected requirement for anticoagulant therapy [except for low-dose aspirin
             ≤ 325 mg/d or Plavix® ≤ 75 mg/d].

          -  Current or expected treatment with phenytoin for the duration of the study.

          -  Known hypersensitivity to NSAIDs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwyn Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes and Glandular Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

